At the time of writing, Abbvie Inc [ABBV] stock is trading at $180.57, down -0.27%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ABBV shares have gain 2.57% over the last week, with a monthly amount glided 4.20%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 7, March 2024, AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference. In a post published today on Yahoo Finance, AbbVie (NYSE: ABBV) will participate in the Barclays 26th Annual Global Healthcare Conference on Thursday, March 14, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 8:00 a.m. Central time.
From an analyst’s perspective:
Abbvie Inc [NYSE: ABBV] stock has seen the most recent analyst activity on January 29, 2024, when William Blair upgraded its rating to a Outperform. Previously, HSBC Securities downgraded its rating to Hold on December 18, 2023. On December 11, 2023, upgrade upgraded it’s rating to Buy. Deutsche Bank started tracking the stock assigning a Hold rating and suggested a price target of $150 on November 09, 2023. Barclays upgraded its rating to a Overweight and raised its price target to $170 on October 30, 2023. In a note dated September 29, 2023, Raymond James initiated an Outperform rating and provided a target price of $177 on this stock.
For the past year, the stock price of Abbvie Inc fluctuated between $130.96 and $182.16. Currently, Wall Street analysts expect the stock to reach $158.41 within the next 12 months. Abbvie Inc [NYSE: ABBV] shares were valued at $180.57 at the most recent close of the market. An investor can expect a potential drop of -12.27% based on the average ABBV price forecast.
Analyzing the ABBV fundamentals
According to Abbvie Inc [NYSE:ABBV], the company’s sales were 54.32B for trailing twelve months, which represents an -5.42% plunge. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.12%, and Net Profit Margin reading is 0.09%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.4 and Total Capital is 0.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 5.73.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 179.27 points at the first support level, and at 177.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 182.15, and for the 2nd resistance point, it is at 183.72.
Abbvie Inc [ABBV] reported earnings per share of $2.79 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $2.77/share, meaning a difference of $0.02 and a surprise factor of 0.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $2.95 per share as compared to estimates of $2.86 per share, a difference of $0.09 representing a surprise of 3.10%.
Ratios To Look Out For
It is important to note that Abbvie Inc [NYSE:ABBV] has a current ratio of 0.87. Further, the Quick Ratio stands at 0.76, while the Cash Ratio is 0.34. Considering the valuation of this stock, the price to sales ratio is 5.87, the price to book ratio is 30.78 and price to earnings (TTM) ratio is 66.38.
Transactions by insiders
Recent insider trading involved RICHMOND TIMOTHY J., EVP, CHIEF HR OFFICER, that happened on Mar 01 ’24 when 75680.0 shares were sold. PRES & CHIEF OPERATING OFFICER, Michael Robert A. completed a deal on Feb 29 ’24 to sell 68879.0 shares. Meanwhile, EVP, GC AND SECRETARY Siatis Perry C sold 9891.0 shares on Feb 29 ’24.
